1541.Hk
The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biotech products and services.
Business. The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biotech products and services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biotech products and services.
The company maintains a strong liquidity position, with a current ratio of 3.83, indicating that it has sufficient short-term assets to cover its short-term liabilities. Its cash and equivalents amount to 679.56 million CNY, which is a significant portion of its total assets of 1.098 billion CNY. The debt-to-equity ratio is 0.29, suggesting a relatively low level of leverage and a conservative capital structure.
Profitability metrics show a challenging performance, with a return on equity of -27.62% and a return on assets of -19.9%. These negative returns indicate that the company is not generating profits relative to its equity or total assets. The operating income is negative at -213.96 million CNY, and the net income is also negative at -218.58 million CNY, reflecting ongoing losses.
The company's revenue is concentrated in a single business segment, as disclosed in its latest financial report, with no significant geographic diversification mentioned. This concentration may expose the company to higher risks if the segment or region experiences a downturn.
Looking ahead, the company is expected to face continued financial challenges, with no significant revenue growth indicated in the outlook. The operating and net losses are likely to persist unless there are substantial improvements in cost management or revenue generation. The company's future performance will depend heavily on its ability to bring new products to market and achieve commercial success.
The risk assessment indicates a low level of liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative net income and operating income suggest that it may need to raise additional capital in the future, which could lead to dilution for existing shareholders. The dilution potential is currently assessed as low, but this could change if the company's financial situation deteriorates.
Recent events, as disclosed in the latest financial filings, do not indicate any major changes in the company's operations or financial strategy. The company continues to focus on its core biotechnology and medical research activities, with no significant new initiatives or partnerships announced.
- The company has a strong liquidity position with a current ratio of 3.83 and significant cash reserves.
- Profitability is a major concern, with negative returns on equity and assets, and ongoing operating and net losses.
- Revenue is concentrated in a single business segment, which may increase risk exposure.
- The company is expected to continue facing financial challenges unless there are improvements in cost management or revenue generation.
- There is currently a low risk of liquidity and dilution, but this could change if the company's financial situation deteriorates.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Return On Assetsnet_income / total_assets
- 1541.HK Market data — financials · 2026-05-26